Literature DB >> 29719366

Olaratumab (Lartruvo): An Innovative Treatment for Soft Tissue Sarcoma.

Lindsey Penniman, Sapna Parmar, Khilna Patel.   

Abstract

Olaratumab (Lartruvo): an innovative treatment for soft tissue sarcoma.

Entities:  

Year:  2018        PMID： 29719366      PMCID： PMC5912242     

Source DB:  PubMed          Journal:  P T        ISSN： 1052-1372


  7 in total

1.  Randomized comparison of doxorubicin and vindesine to doxorubicin for patients with metastatic soft-tissue sarcomas.

Authors:  E C Borden; D A Amato; J H Edmonson; P S Ritch; M Shiraki
Journal:  Cancer       Date:  1990-09-01       Impact factor: 6.860

2.  Cancer Statistics, 2017.

Authors:  Rebecca L Siegel; Kimberly D Miller; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2017-01-05       Impact factor: 508.702

3.  PICASSO III: A Phase III, Placebo-Controlled Study of Doxorubicin With or Without Palifosfamide in Patients With Metastatic Soft Tissue Sarcoma.

Authors:  Christopher W Ryan; Ofer Merimsky; Mark Agulnik; Jean-Yves Blay; Scott M Schuetze; Brian A Van Tine; Robin L Jones; Anthony D Elias; Edwin Choy; Thierry Alcindor; Vicki L Keedy; Damon R Reed; Robert N Taub; Antoine Italiano; Xavier Garcia Del Muro; Ian R Judson; Jill Y Buck; Francois Lebel; Jonathan J Lewis; Robert G Maki; Patrick Schöffski
Journal:  J Clin Oncol       Date:  2016-09-30       Impact factor: 44.544

4.  Olaratumab and doxorubicin versus doxorubicin alone for treatment of soft-tissue sarcoma: an open-label phase 1b and randomised phase 2 trial.

Authors:  William D Tap; Robin L Jones; Brian A Van Tine; Bartosz Chmielowski; Anthony D Elias; Douglas Adkins; Mark Agulnik; Matthew M Cooney; Michael B Livingston; Gregory Pennock; Meera R Hameed; Gaurav D Shah; Amy Qin; Ashwin Shahir; Damien M Cronier; Robert Ilaria; Ilaria Conti; Jan Cosaert; Gary K Schwartz
Journal:  Lancet       Date:  2016-06-09       Impact factor: 79.321

5.  Doxorubicin versus CYVADIC versus doxorubicin plus ifosfamide in first-line treatment of advanced soft tissue sarcomas: a randomized study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group.

Authors:  A Santoro; T Tursz; H Mouridsen; J Verweij; W Steward; R Somers; J Buesa; P Casali; D Spooner; E Rankin
Journal:  J Clin Oncol       Date:  1995-07       Impact factor: 44.544

6.  Frequency of certain established risk factors in soft tissue sarcomas in adults: a prospective descriptive study of 658 cases.

Authors:  Nicolas Penel; Jessica Grosjean; Yves Marie Robin; Luc Vanseymortier; Stéphanie Clisant; Antoine Adenis
Journal:  Sarcoma       Date:  2008

7.  Phase I study of olaratumab in Japanese patients with advanced solid tumors.

Authors:  Toshihiko Doi; Yan Ma; Aruna Dontabhaktuni; Cornelia Nippgen; Johannes Nippgen; Atsushi Ohtsu
Journal:  Cancer Sci       Date:  2014-06-27       Impact factor: 6.716
  7 in total
  1 in total

1.  Olaratumab's failure in soft tissue sarcoma.

Authors:  Maroun Bou Zerdan; Aram H Bidikian; Ibrahim Alameh; Clara El Nakib; Hazem I Assi
Journal:  Rare Tumors       Date:  2021-07-18
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.